scholarly journals Antibody-Dependent Enhancement of Ebola Virus Infection

2003 ◽  
Vol 77 (13) ◽  
pp. 7539-7544 ◽  
Author(s):  
Ayato Takada ◽  
Heinz Feldmann ◽  
Thomas G. Ksiazek ◽  
Yoshihiro Kawaoka
Keyword(s):  
Virus Infection ◽  
Ebola Virus ◽  
Human Populations ◽  
Hemorrhagic Disease ◽  
Viral Infectivity ◽  
Kidney Cells ◽  
Emerging Pathogens ◽  
Viral Glycoprotein ◽  
Antibody Dependent Enhancement ◽  
Ebola Virus Infection

ABSTRACT Most strains of Ebola virus cause a rapidly fatal hemorrhagic disease in humans, yet there are still no biologic explanations that adequately account for the extreme virulence of these emerging pathogens. Here we show that Ebola Zaire virus infection in humans induces antibodies that enhance viral infectivity. Plasma or serum from convalescing patients enhanced the infection of primate kidney cells by the Zaire virus, and this enhancement was mediated by antibodies to the viral glycoprotein and by complement component C1q. Our results suggest a novel mechanism of antibody-dependent enhancement of Ebola virus infection, one that would account for the dire outcome of Ebola outbreaks in human populations.

scholarly journals Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks

2015 ◽  
Vol 59 (10) ◽  
pp. 5892-5902 ◽  
Author(s):  
Azizul Haque ◽  
Didier Hober ◽  
Joel Blondiaux
Keyword(s):  
Virus Infection ◽  
Ebola Virus ◽  
Therapeutic Agent ◽  
Cell Types ◽  
Rapid Evaluation ◽  
Hemorrhagic Disease ◽  
Treatment And Prevention ◽  
Approved Drugs ◽  
Ebola Virus Infection

ABSTRACTEbola virus can cause severe hemorrhagic disease with high fatality rates. Currently, no specific therapeutic agent or vaccine has been approved for treatment and prevention of Ebola virus infection of humans. Although the number of Ebola cases has fallen in the last few weeks, multiple outbreaks of Ebola virus infection and the likelihood of future exposure highlight the need for development and rapid evaluation of pre- and postexposure treatments. Here, we briefly review the existing and future options for anti-Ebola therapy, based on the data coming from rare clinical reports, studies on animals, and results fromin vitromodels. We also project the mechanistic hypotheses of several potential drugs against Ebola virus, including small-molecule-based drugs, which are under development and being tested in animal models orin vitrousing various cell types. Our paper discusses strategies toward identifying and testing anti-Ebola virus properties of known and medically approved drugs, especially those that can limit the pathological inflammatory response in Ebola patients and thereby provide protection from mortality. We underline the importance of developing combinational therapy for better treatment outcomes for Ebola patients.

scholarly journals A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection

2020 ◽  
Vol 14 (9) ◽  
pp. e0008602 ◽  
Author(s):  
Wakako Furuyama ◽  
Asuka Nanbo ◽  
Junki Maruyama ◽  
Andrea Marzi ◽  
Ayato Takada
Keyword(s):  
Virus Infection ◽  
Ebola Virus ◽  
Complement Component ◽  
Antibody Dependent Enhancement ◽  
Ebola Virus Infection

scholarly journals Fcγ-receptor IIa-mediated Src Signaling Pathway Is Essential for the Antibody-Dependent Enhancement of Ebola Virus Infection

2016 ◽  
Vol 12 (12) ◽  
pp. e1006139 ◽  
Author(s):  
Wakako Furuyama ◽  
Andrea Marzi ◽  
Aaron B. Carmody ◽  
Junki Maruyama ◽  
Makoto Kuroda ◽  
...  
Keyword(s):  
Virus Infection ◽  
Signaling Pathway ◽  
Ebola Virus ◽  
Fcγ Receptor ◽  
Antibody Dependent Enhancement ◽  
Src Signaling ◽  
Ebola Virus Infection

scholarly journals Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors

Cell Reports ◽  
2018 ◽  
Vol 24 (7) ◽  
pp. 1802-1815.e5 ◽  
Author(s):  
Natalia A. Kuzmina ◽  
Patrick Younan ◽  
Pavlo Gilchuk ◽  
Rodrigo I. Santos ◽  
Andrew I. Flyak ◽  
...  
Keyword(s):  
Virus Infection ◽  
Ebola Virus ◽  
Antibody Dependent Enhancement ◽  
Human Antibodies ◽  
Ebola Virus Infection

Epitopes Required for Antibody‐Dependent Enhancement of Ebola Virus Infection

2007 ◽  
Vol 196 (s2) ◽  
pp. S347-S356 ◽  
Author(s):  
Ayato Takada ◽  
Hideki Ebihara ◽  
Heinz Feldmann ◽  
Thomas W. Geisbert ◽  
Yoshihiro Kawaoka
Keyword(s):  
Virus Infection ◽  
Ebola Virus ◽  
Antibody Dependent Enhancement ◽  
Ebola Virus Infection

scholarly journals Profiling the Native Specific Human Humoral Immune Response to Sudan Ebola Virus Strain Gulu by Chemiluminescence Enzyme-Linked Immunosorbent Assay

2012 ◽  
Vol 19 (11) ◽  
pp. 1844-1852 ◽  
Author(s):  
Ariel Sobarzo ◽  
Eddie Perelman ◽  
Allison Groseth ◽  
Olga Dolnik ◽  
Stephan Becker ◽  
...  
Keyword(s):  
Virus Infection ◽  
Immunosorbent Assay ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Viral Proteins ◽  
Enzyme Linked Immunosorbent Assay ◽  
Viral Glycoprotein ◽  
Lethal Challenge ◽  
Content Type ◽  
Ebola Virus Infection

ABSTRACTEbolavirus, a member of the familyFiloviridae, causes high lethality in humans and nonhuman primates. Research focused on protection and therapy for Ebola virus infection has investigated the potential role of antibodies. Recent evidence suggests that antibodies can be effective in protection from lethal challenge with Ebola virus in nonhuman primates. However, despite these encouraging results, studies have not yet determined the optimal antibodies and composition of an antibody cocktail, if required, which might serve as a highly effective and efficient prophylactic. To better understand optimal antibodies and their targets, which might be important for protection from Ebola virus infection, we sought to determine the profile of viral protein-specific antibodies generated during a natural cycle of infection in humans. To this end, we characterized the profile of antibodies against individual viral proteins of Sudan Ebola virus (Gulu) in human survivors and nonsurvivors of the outbreak in Gulu, Uganda, in 2000-2001. We developed a unique chemiluminescence enzyme-linked immunosorbent assay (ELISA) for this purpose based on the full-length recombinant viral proteins NP, VP30, and VP40 and two recombinant forms of the viral glycoprotein (GP1-294and GP1-649) of Sudan Ebola virus (Gulu). Screening results revealed that the greatest immunoreactivity was directed to the viral proteins NP and GP1-649, followed by VP40. Comparison of positive immunoreactivity between the viral proteins NP, GP1-649, and VP40 demonstrated a high correlation of immunoreactivity between these viral proteins, which is also linked with survival. Overall, our studies of the profile of immunorecognition of antibodies against four viral proteins of Sudan Ebola virus in human survivors may facilitate development of effective monoclonal antibody cocktails in the future.

Sign in / Sign up

Export Citation Format

Share Document